Replimune Group (NASDAQ:REPL) Upgraded by Piper Sandler to "Overweight" Rating

Key Points

• The Replimune Group has been upgraded by Piper Sandler from a "neutral" to an "overweight" rating, with a price target of $13.00, suggesting a potential upside of 45.25% from its current stock price.
• Despite the upgrade, other analysts have taken a mixed stance, with ratings varying from "strong-buy" to "sell," indicating a lack of consensus on the stock's performance.
• Replimune reported a quarterly loss of ($0.95) earnings per share, falling short of analysts' expectations, and is anticipated to have an average earnings per share of (-2.97) for the current fiscal year.

Replimune Group (NASDAQ:REPL - Get Free Report) was upgraded by research analysts at Piper Sandler from a "neutral" rating to an "overweight" rating in a note issued to investors on Monday,Briefing.com Automated Import reports. The firm currently has a $13.00 price target on the stock. Piper Sandler's price objective would suggest a potential upside of 45.25% from the company's current price.

REPL has been the topic of a number of other reports. Leerink Partnrs lowered Replimune Group from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, July 22nd. Weiss Ratings restated a "sell (d-)" rating on shares of Replimune Group in a research report on Tuesday, October 14th. HC Wainwright reaffirmed a "neutral" rating on shares of Replimune Group in a research note on Monday, September 8th. JPMorgan Chase & Co. raised shares of Replimune Group from an "underweight" rating to a "neutral" rating in a research note on Monday. Finally, Wedbush upgraded Replimune Group from a "neutral" rating to an "outperform" rating and increased their price objective for the company from $4.00 to $18.00 in a research report on Monday. Five equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Hold" and an average target price of $10.75.

Replimune Group Price Performance

Shares of NASDAQ REPL traded up $4.45 during midday trading on Monday, reaching $8.95. 110,111,491 shares of the company traded hands, compared to its average volume of 4,509,422. Replimune Group has a 12 month low of $2.68 and a 12 month high of $17.00. The company has a debt-to-equity ratio of 0.21, a quick ratio of 6.94 and a current ratio of 6.94. The stock's 50-day simple moving average is $5.03 and its 200-day simple moving average is $7.27. The firm has a market cap of $698.64 million, a PE ratio of -2.76 and a beta of 0.42.

Replimune Group (NASDAQ:REPL - Get Free Report) last announced its earnings results on Thursday, August 7th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.83) by ($0.12). As a group, equities analysts anticipate that Replimune Group will post -2.97 earnings per share for the current fiscal year.

Insider Activity

In other news, CFO Emily Luisa Hill sold 9,154 shares of the company's stock in a transaction dated Friday, August 15th. The stock was sold at an average price of $5.37, for a total transaction of $49,156.98. Following the completion of the transaction, the chief financial officer directly owned 134,368 shares of the company's stock, valued at $721,556.16. This represents a 6.38% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 5.20% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Replimune Group

Hedge funds have recently bought and sold shares of the company. US Bancorp DE raised its stake in Replimune Group by 582.6% in the 1st quarter. US Bancorp DE now owns 4,594 shares of the company's stock valued at $45,000 after acquiring an additional 3,921 shares during the period. BNP Paribas Financial Markets raised its position in shares of Replimune Group by 37.5% in the second quarter. BNP Paribas Financial Markets now owns 6,889 shares of the company's stock valued at $64,000 after purchasing an additional 1,879 shares during the period. Raymond James Financial Inc. bought a new position in shares of Replimune Group in the second quarter valued at about $69,000. Griffin Asset Management Inc. acquired a new stake in shares of Replimune Group during the 3rd quarter worth about $82,000. Finally, Tower Research Capital LLC TRC boosted its holdings in shares of Replimune Group by 2,020.8% during the 2nd quarter. Tower Research Capital LLC TRC now owns 9,692 shares of the company's stock worth $90,000 after buying an additional 9,235 shares during the period. 92.53% of the stock is currently owned by institutional investors and hedge funds.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.